ES8400145A1 - "procedimiento para la preparacion de polipeptidos inmunogenamente activos y producidos microbianamente, para la obtencion de una vacuna contra la fiebre aftosa". - Google Patents

"procedimiento para la preparacion de polipeptidos inmunogenamente activos y producidos microbianamente, para la obtencion de una vacuna contra la fiebre aftosa".

Info

Publication number
ES8400145A1
ES8400145A1 ES513159A ES513159A ES8400145A1 ES 8400145 A1 ES8400145 A1 ES 8400145A1 ES 513159 A ES513159 A ES 513159A ES 513159 A ES513159 A ES 513159A ES 8400145 A1 ES8400145 A1 ES 8400145A1
Authority
ES
Spain
Prior art keywords
coli
produced
fmdv
plasmid
foot
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES513159A
Other languages
English (en)
Other versions
ES513159A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ES513159A0 publication Critical patent/ES513159A0/es
Publication of ES8400145A1 publication Critical patent/ES8400145A1/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROCEDIMIENTO PARA LA PREPARACION DE UN POLIPEPTIDO INMUNOLOGICAMENTE ACTIVO, UTIL PARA OBTENER UNA VACUNA CONTRA LA FIEBRE AFTOSA.SE EMPLEA UN POLIPEPTIDO QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE AL MENOS UN DETERMINANTE ANTIGENO DE PROTEINA DE VIRUS DE FIEBRE AFTOSA O BIEN DOS DETERMINANTES ANTIGENOS, PROVENIENTES DE, POR LO MENOS, DOS CEPAS DIFERENTES DEL VIRUS DE FIEBRE AFTOSA O UNO DE LOS PROCEDENTES POLIPEPTIDOS FUSIONADO CON UN POLIPEPTIDO DERIVADO DE LA EXPRESION DE ADN ADICIONAL; SE UTILIZA UN VEHICULO DE EXPRESION MICROBIANA, CAPAZ DE EXPRESARDICHO POLIPEPTIDO EN UN MICROORGANISMO TRANSFORMANTE. EL CULTIVO MICROBIANO TRANSFORMADO, ES UN CULTIVO DE E. COLI. EL VEHICULO MICROBIANO REPLICABLE SE SELECCIONA DEL GRUPO COMPUESTO POR PFM1; PFM2; PFM3; PFM10; PFM20; PFMB1; PFMC; PFMD; P FMF; Y PFMG.
ES513159A 1981-06-16 1982-06-16 "procedimiento para la preparacion de polipeptidos inmunogenamente activos y producidos microbianamente, para la obtencion de una vacuna contra la fiebre aftosa". Expired ES8400145A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27410381A 1981-06-16 1981-06-16
US37485582A 1982-05-04 1982-05-04

Publications (2)

Publication Number Publication Date
ES513159A0 ES513159A0 (es) 1983-11-01
ES8400145A1 true ES8400145A1 (es) 1983-11-01

Family

ID=26956602

Family Applications (1)

Application Number Title Priority Date Filing Date
ES513159A Expired ES8400145A1 (es) 1981-06-16 1982-06-16 "procedimiento para la preparacion de polipeptidos inmunogenamente activos y producidos microbianamente, para la obtencion de una vacuna contra la fiebre aftosa".

Country Status (8)

Country Link
EP (1) EP0068693A3 (es)
BR (1) BR8203507A (es)
DK (1) DK268882A (es)
ES (1) ES8400145A1 (es)
GB (1) GB2103622B (es)
IE (1) IE53375B1 (es)
PT (1) PT75050B (es)
ZW (1) ZW11982A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8105516L (sv) * 1980-09-18 1982-03-19 Wellcome Found Syntetisk dna och forfarande for framstellning derav
US4719177A (en) * 1981-04-20 1988-01-12 Massachusetts Institute Of Technology Production of complementary DNA representing RNA viral sequences by recombinant DNA methods and uses therefor
CA1338705C (en) * 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes
EP0105346B1 (en) * 1982-04-14 1991-11-13 BITTLE, James L. Synthetic picornavirus antigen
US5230888A (en) * 1982-05-06 1993-07-27 Massachusetts Institute Of Technology Production of neutralizing antibodies by polypeptide VP1 of enteroviruses and by oligopeptide fragments of polypeptide VP1
US4751083A (en) * 1982-05-06 1988-06-14 Massachusetts Institute Of Technology Production of neutralizing antibodies by polypeptide VP1 of enteroviruses and by oligopeptide fragments of polypeptide VP1
EP0105481A1 (en) * 1982-09-30 1984-04-18 The Wellcome Foundation Limited Novel antigens and vaccines containing them
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4599197A (en) * 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4518526A (en) * 1982-12-22 1985-05-21 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
WO1984003506A1 (en) * 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
US4769237A (en) * 1983-03-25 1988-09-06 Bittle James L Synthetic picornavirus antigen
NZ209308A (en) 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US4701416A (en) * 1983-12-09 1987-10-20 Cetus Corporation Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV
US4732971A (en) * 1985-06-03 1988-03-22 Eli Lilly And Company Synthetic vaccines for foot and mouth disease
US5539092A (en) * 1992-10-02 1996-07-23 Arch Development Corporation Cyanobacterial and plant acetyl-CoA carboxylase
US6306636B1 (en) 1997-09-19 2001-10-23 Arch Development Corporation Nucleic acid segments encoding wheat acetyl-CoA carboxylase
NZ556635A (en) 2004-12-22 2010-11-26 Genentech Inc Method for producing soluble multi-membrane-spanning proteins
CN101795703B (zh) 2007-06-27 2015-05-06 里兰斯坦福初级大学理事会 肽酪氨酸酶抑制剂及其应用
CN104792990A (zh) * 2015-03-31 2015-07-22 洛阳莱普生信息科技有限公司 一种a型口蹄疫竞争elisa抗体检测试剂盒
CN105399802B (zh) * 2015-12-08 2020-04-03 中国农业科学院兰州兽医研究所 A型口蹄疫基因工程复合表位蛋白及疫苗
CN105622762B (zh) * 2016-03-03 2020-04-03 中国农业科学院兰州兽医研究所 一种牛趋化因子介导的o型口蹄疫靶向性复合表位蛋白及疫苗
CN105777909B (zh) * 2016-03-03 2020-04-03 中国农业科学院兰州兽医研究所 一种猪趋化因子介导的a型口蹄疫靶向性复合表位蛋白及疫苗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK207681A (da) * 1980-05-12 1981-11-13 Biogen Nv Dna-sekvenser rekombinations-dna-molekyler og fremgangsmaade klovsyge virale antigener til fremstilling af polypeptider med specificitet som mund og
PH22618A (en) * 1980-06-06 1988-10-28 Biogen Nv Improved vectors and method for making such vectors and for expressing cloned genes
SE8105516L (sv) * 1980-09-18 1982-03-19 Wellcome Found Syntetisk dna och forfarande for framstellning derav

Also Published As

Publication number Publication date
GB2103622B (en) 1986-01-15
EP0068693A2 (en) 1983-01-05
PT75050A (en) 1982-07-01
ES513159A0 (es) 1983-11-01
DK268882A (da) 1983-02-02
IE53375B1 (en) 1988-10-26
ZW11982A1 (en) 1982-11-10
BR8203507A (pt) 1983-06-07
GB2103622A (en) 1983-02-23
PT75050B (en) 1984-02-21
EP0068693A3 (en) 1983-07-20
IE821428L (en) 1982-12-16

Similar Documents

Publication Publication Date Title
ES8400145A1 (es) "procedimiento para la preparacion de polipeptidos inmunogenamente activos y producidos microbianamente, para la obtencion de una vacuna contra la fiebre aftosa".
US4755465A (en) Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
EP0055945A2 (en) Human proinsulin and analogs thereof and method of preparation by microbial polypeptide expression and conversion thereof to human insulin
DE68929507D1 (de) Rekombinante mykobakterielle expressions-träger sowie deren verwendung
Makoff et al. Expression of tetanus toxin fragment C in E. coli: its purification and potential use as a vaccine
US5928644A (en) T-cell epitopes
EA199700244A1 (ru) Слитый белок, экспрессирующий вектор, рекомбинантный штамм, вакцинный препарат
WO1991011525A3 (en) Vaccines
EP0327377A3 (en) Kex2 endoprotease and process for production thereof
KR870009025A (ko) 재조합 숙주로부터 제조한 아프로티닌 동족체, 그의 방법, 표현 벡타 및 재조합 숙주 및 그의 재약상 용도
KR870005098A (ko) 융합 단백질의 제조방법
WO1993022332A3 (en) Recombinant production of immunoglobulin-like domains in prokaryotic cells
NZ218332A (en) Il-4(interleukin-4), recombinant production, dna, vectors and pharmaceutical composition
IL60714A (en) Process for the preparation of e.coli phoa mutants and plasmids coding for alkaline phosphatase and products thereof
KR950000301B1 (ko) 진핵 밸러스트 부분(ballast portion)을 갖는 융합 단백질의 제조방법
IL90035A (en) Synthetic multimeric hepatitis b virus vaccine including both t cell and b cell determinants
Slos et al. Recombinant cholera toxin B-subunit in Escherichia coli: high-level secretion, purification, and characterization
AU2795989A (en) Production of gonorrheal pi proteins and vaccines
ATE480554T1 (de) Rekombinanter leukotoxinimpfstoff aus fusobacterium necrophorum und dessen präparation
Olsen et al. Enhancement of heterologous polypeptide expression by alterations in the ribosome-binding-site sequence
EP0138644A1 (en) Novel plasmid vectors
IE831099L (en) Cloning vehicles for polypeptide expression in microbial¹hosts
KR870007280A (ko) 바실러스에서의 사람 혈청 알부민의 제조방법
EP0257721A3 (en) Vaccine
KR850006703A (ko) 재조합체 dna 발현 벡터의 제조방법